Kia ora We were deeply saddened to learn that Joy Wilkie died this week. Diagnosed in 2015, Joy has been a trustee of Myeloma New Zealand since 2016...
Myeloma NZ
Our last online catch up was on 28 November. A big thank you to patient Mike Woods for hosting. We don’t have a date for our next online group yet...
Malignant Haematology RESEARCH REVIEW – Issue 11 – 2025
Issue 11 2025 of the Malignant Haematology RESEARCH REVIEW™ is now out. In it you can read about: New Zealand multiple myeloma patients demonstrate...
Collective statement from consumer and patient representative groups on Pharmac’s proposal to decline some medicine funding applications on the Options for Investment list.
Myeloma New Zealand and other consumer and patient representative groups have sent a collective statement to Pharmac regarding their proposal to...
MNZ online “coffee group” / virtual support group
MNZ online “coffee group”/virtual support group Our next online catch up is at 11am on Friday 28 November. Hosted by patient Mike Woods, you are...
Latest email
You can read our latest email here Sign up for our emails on our website and tick "newsletter sign up".
Myeloma New Zealand’s feedback to Pharmac’s proposal to decline some medicine funding applications on the Options for Investment list
Phamac have proposed to decline some medicine funding applications on the Options for Investment list. You can read about their proposal here....
Move for Myeloma in November 2025
Do you remember last year when myeloma patient Toby and his friend Ben ran an amazing 50km to raise money for Myeloma New Zealand? This year they...
Online catch up
We're planning another onling catch up (like an online coffee group) in a couple of weeks - we'll share the date once finalised.
Zoom catch up/support group
At 3pm on Saturday 18 October we will be holding a group video call/chat - all welcome! Like our previous ones, it will be a very informal catch...
Letter to Pharmac in support of application for belantamab mafodotin
Pharmac have received an application for belantamb mafodotin. The application has been assigned to Pharmac's Cancer Treatments Advisory Committee...
SUCCESSOR-1 trial for relapsed/refractory myeloma
The SUCCESSOR-1 trial closes for recruitment in about four months. You can watch a very short video about it and results so far...